TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
23.345
+0.415 (+1.81%)
As of 11:31AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close22.930
Open22.880
Bid23.360 x 1500
Ask23.370 x 300
Day's Range22.850 - 23.410
52 Week Range10.850 - 33.240
Volume1,901,768
Avg. Volume11,342,517
Market Cap23.776B
Beta1.11
PE Ratio (TTM)N/A
EPS (TTM)-15.793
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est20.43
Trade prices are not sourced from all markets
  • Business Wire6 days ago

    Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report

    Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company’s initiatives: building healthy communities and leading a responsible business. Teva’s 2017 Social Impact Report spotlights the company’s commitment to corporate responsibility and transparency, and provides context on its efforts to contribute to healthy communities in ways the business can uniquely support—through safe medicines, collaboration, health initiatives and innovative research. Operating as an ethical, enduring enterprise is critical to continue bringing value to our business, our stakeholders and society,” said Kåre Schultz, President and CEO of Teva.

  • FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%
    Market Realist7 days ago

    FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%

    On July 13, the FDA announced a voluntary recall of drugs containing valsartan and valsartan/hydrochlorothiazide API (active pharmaceutical ingredient) manufactured by Solco Healthcare, Major Pharmaceuticals, and Teva Pharmaceutical (TEVA). The drugs are used for the treatment of heart failure and high blood pressure.

  • Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018
    Motley Fool8 days ago

    Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018

    Demand for generic drugs is on the rise, and investors are convinced the trend will keep this profitable company moving in the right direction.

  • 3 Warren Buffett Stocks Worth Buying Now
    Motley Fool10 days ago

    3 Warren Buffett Stocks Worth Buying Now

    These three stocks are backed by Buffett and Berkshire and could help power your portfolio to market-beating returns.

  • 4 Warren Buffett Stocks to Buy in Q2 Earnings
    Zacks10 days ago

    4 Warren Buffett Stocks to Buy in Q2 Earnings

    We highlight four of the Oracle of Omaha's sought-after companies that are likely to report upbeat second-quarter earnings.

  • Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?
    Zacks12 days ago

    Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?

    Is (TEVA) Outperforming Other Medical Stocks This Year?

  • Business Wire12 days ago

    Teva to Report Second Quarter 2018 Financial Results on August 2, 2018

    Teva Pharmaceutical Industries Ltd. (TEVA) announced today that it will release its second quarter 2018 financial results on Thursday, August 2, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its second quarter 2018 results and overall business environment.

  • Teva Announces Launch of Generic Version of Uceris in US
    Market Realist13 days ago

    Teva Announces Launch of Generic Version of Uceris in US

    On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.

  • Business Wire14 days ago

    Teva Announces Launch of a Generic Version of Uceris® in the United States

    Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris®1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. “The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, EVP and head of North America Commercial.

  • TEVA or AKRX: Which Is the Better Value Stock Right Now?
    Zacks14 days ago

    TEVA or AKRX: Which Is the Better Value Stock Right Now?

    TEVA vs. AKRX: Which Stock Is the Better Value Option?

  • Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?
    Market Realist14 days ago

    Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?

    As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.

  • Teva Presented New Data on Fremanezumab: What You Should Know
    Market Realist14 days ago

    Teva Presented New Data on Fremanezumab: What You Should Know

    During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.

  • ACCESSWIRE14 days ago

    Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

    Stock Research Monitor: DEPO, DRRX, and ENDP LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • Morningstar14 days ago

    Biogen Scores Surprise Win

    Alzheimer's therapy shows promising results.

  • Teva Pharmaceutical Stock in the Week Ended July 6
    Market Realist17 days ago

    Teva Pharmaceutical Stock in the Week Ended July 6

    On July 5, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $23.92, a fall of 3.2% compared to the previous day. TEVA stock was trading 121% higher than its 52-week low of $10.85 on November 2, 2017. Currently, Teva Pharmaceutical stock is trading higher than its 50-day moving average of $22.56 as well as its 200-day moving average of $19.85.

  • Analyst Recommendations for Teva Pharmaceutical in July
    Market Realist17 days ago

    Analyst Recommendations for Teva Pharmaceutical in July

    Teva Pharmaceutical Industries (TEVA) is one of the largest generic drug manufacturers. It has been recuperating from its recent troubles as it started facing generic competition for its key product Copaxone. Warren Buffet’s Berkshire Hathaway initiated investment in Teva in the previous quarter and increased it in the recently reported quarter.

  • Virtual doctor start-up American Well is raising over $300 million and Philips is a new investor
    CNBC21 days ago

    Virtual doctor start-up American Well is raising over $300 million and Philips is a new investor

    American Well is raising over $300 million for telemedicine, and Philips is a new investor

  • ACCESSWIRE24 days ago

    Today’s Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs 500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded.

  • Teva to Present New Data for Fremanezumab
    Market Realist25 days ago

    Teva to Present New Data for Fremanezumab

    Today, Teva Pharmaceutical Industries (TEVA) announced that it will present new data for its migraine drug Fremanezumab, which is under review by the FDA for the preventive treatment as a monthly or quarterly injection, at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The event is being held from June 28 to July 1. Teva plans to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab.

  • Business Wire25 days ago

    Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Society’s 60th Annual Scientific Meeting

    Teva Pharmaceutical Industries Ltd. today announced 23 abstracts, one late-breaking poster and three oral presentations of fremanezumab for the preventive treatment of migraine which will be presented at the American Headache Society’s 60th Annual Scientific Meeting in San Francisco from June 28-July 1, 2018.

  • Stocks - ConAgra, Pinnacle Foods Tumble in Pre-Market, WWE Surges
    Investing.com26 days ago

    Stocks - ConAgra, Pinnacle Foods Tumble in Pre-Market, WWE Surges

    Investing.com - Stocks in focus in pre-market trade Wednesday:

  • 3 Best Big Pharma Stocks of 2018 So Far
    Motley Fool27 days ago

    3 Best Big Pharma Stocks of 2018 So Far

    Are any of these biggest year-to-date winners smart picks for the long term?

  • Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical
    Market Realistlast month

    Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical

    On June 11, Leerink raised its 12-month target price on Teva from $13 to $16 while maintaining its “underperform” rating on the stock. Leerink analyst Ami Fadia revised the target prices to better reflect the improving dynamics of the company.

  • Teva to Discontinue a Fremanezumab Study on Cluster Headache
    Zackslast month

    Teva to Discontinue a Fremanezumab Study on Cluster Headache

    Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.

  • A Look at Teva’s Generic Drugs Research Pipeline
    Market Realistlast month

    A Look at Teva’s Generic Drugs Research Pipeline

    Teva Pharmaceutical Industries (TEVA) is the largest generics pharma manufacturer in the world. In particular, the FDA is approving generics versions of branded drugs more rapidly to shift toward a more affordable healthcare structure. Teva is on track to achieve targeted cost reductions and revenue growth.